17.09.2020 • Topics

Accelerated Drug Discovery

In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.

Continue with login

No account yet?

Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.

Register

Company

Logo:

Schrödinger GmbH

Thierschstraße 27
80538 München
Germany

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read